• Active, not recruiting

NCT03859427: Phase 3: Once-weekly vs Twice-wkly Carfilzomib + Lenalidomide + Dex RRMM - A.R.R.O.W.2

Updated: May 26

A.R.R.O.W.2

NCT03859427: Phase 3: A Study Comparing Once-weekly vs Twice-weekly Carfilzomib in Combination With Lenalidomide and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma (ARROW2)

KRd


ARROW TRIAL KRD MYELOMA


A Study Comparing Once-weekly vs Twice-weekly Carfilzomib in Combination With Lenalidomide and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma (ARROW2)


Compare efficacy of 56 mg/m2 carfilzomib administered once-weekly in combination with lenalidomide and dexamethasone (KRd 56 mg/m2) to 27 mg/m2 carfilzomib administered twice-weekly in combination with lenalidomide and dexamethasone (KRd 27 mg/m2) in subjects with relapsed or refractory multiple myeloma (RRMM) with 1 to 3 prior lines of therapy.


Sponsor

Amgen


Multiple Locations

International Study

 

ClinicalTrials.gov Identifier: NCT03859427


Official Title: A Randomized, Open-label, Phase 3 Study Comparing Once-weekly vs Twice-weekly Carfilzomib in Combination With Lenalidomide and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma (A.R.R.O.W.2)


First Posted : March 1, 2019


Click here to see details on ClinicalTrials.gov

 

Dexamethasone : National Cancer Institute

Dexamethasone : MedlinePlus Drug Information

Lenalidomide: National Cancer Institute

Lenalidomide: MedlinePlus Drug Information

Carfilzomib : National Cancer Institute

Carfilzomib : MedlinePlus Drug Information

 

Drug: Carfilzomib

Drug: Lenalidomide

Drug: Dexamethasone

 

Locations

United States, California

United States, Colorado

United States, Connecticut

United States, Florida

United States, Illinois

United States, New York

United States, Ohio

United States, Texas

Europe

France

Germany

Netherlands

Spain

Austria

Bulgaria

Czechia

Finland

Greece

Lithuania

Romania

Slovakia

Sweden

Turkey

Asia

Japan

Russian Federation




Posts Archive